CLINICAL VALUE OF DETERMINING GALECTIN-3 IN PATIENTS WITH CHRONIC HEART FAILURE
https://doi.org/10.21518/2079-701X-2017-7-63-68
Abstract
Relevance: today, the task of finding new biomarkers that could help monitor the effectiveness of pharmacotherapy, ensuring early diagnosis and predicting the clinical outcome of the disease continues to be relevant.
Purpose: the purpose of the study was to assess the clinical value of determining galectin-3 in patients with chronic heart failure (CHF).
Material and methods: the study included 53 patients (women n = 31, men n = 22) with CHF II-III FC NYHA. The mean age of patients was 71 (95% CI 68.99-74.37). The group of patients with CHF II NYHA included 14 people, and the group with CHF III NYHA - 39. The median baseline level for NT-proBNP was 65.7 pmol/L, the median baseline for galectin-3 - 8.37 pmol/L.
Results: increased levels of galectin-3 correlated with reduced EF (%) (R = -0.26, p = 0.04), increased serum creatinine (r = 0.26, p = 0.04) and elevated plasma levels of NT-proBNP (r = 0.3, p = 0.02). No statistically significant relationship was obtained with other clinical indicators, such as SBP, DBP, heart rate, BMI, the 6-minute test, LVMI, LVM, glucose, TC, GFR. We obtained a moderate correlation between the plasma levels of NT-proBNP and galectin-3 (r = 0.3, p = 0.02). Reduced levels of galectin-3 after treatment were observed in 84.3% of patients.
Conclusion. Galectin-3 can be used as an additional diagnostic biomarker for CHF. The incidence of congestive heart failure (CHF) is 1–2% among the population in the developed countries reaching >10% in patients aged over 70 years. [1] Despite a significant progress in the treatment of CHF over the past decades, the mortality rate is very high reaching 60% in men and 45% in women after 5 years after the initial diagnosis. [2] Therefore, the development of new methods for the prevention and treatment of CHF is a relevant medical and social problem.
About the Authors
K. A. Gyamdzhyan
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Moscow
Russian Federation
Moscow
V. G. Kukes
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
MD, Prof., RAS acad.,
Moscow
M. L. Maksimov
Scientific Center for Expertise of Medicinal Products, MoH RF
Russian Federation
Russian Federation
MD, Prof.,
Moscow
References
1. Агеев Ф.Т., Арутюнов Г.П., Беленков Ю.Н. и др. Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа, 2010. 336 с.
2. Ho JE, Liu C, Lyass A et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol, 2012, 60(14): 1249-1256.
3. Агеев Ф.Т., Азизова А.Г. Галектин-3 – новый биохимический маркер сердечной недостаточности. Журнал Сердечная Недостаточность, 2011, 12 (2): 108–114.
4. Николаева М.В., Кургузова Д.О. Механизм образования натрийуретического пептида у больных ХСН. Лекарственные препараты и рациональная фармакотерапия, 2015, 4-5.
5. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA, 2006, 103: 5060–5.
6. Liu YH, d’Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, et al. N-Acetyl-seryl-aspartyllysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growthregulatory lectin. Am J Physiol Heart Circ Physiol, 2009, 296: H404–12.
7. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep, 2010, 7: 1-8.
8. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation, 2004, 110: 3121–8.
9. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol, 2011, 108: 385–90.
10. Ueland T, Aukrust P, Broch K, Aakhus S, Skardal R, Muntendam P, et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol, 2011, 150: 361–4.
11. Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail, 2012, 14: 74–81.
12. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В., Мареев Ю.В., Овчинников А.Г. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность, 2013, 14(7): 379–472.
13. Lok DJ, Van Der Meer P, de la Porte PW et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol, 2010, 99(5): 323–328.
14. Felker GM, Fiuzat M, Shaw LK et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail, 2012, 5(1): 72–78.
15. Biomarker Definitions Working Group. Biomarkers and surrogate end-points: preffered definitions and conceptual framework. Clin Pharmacol Ther, 2001, 69(3): 89–95.
16. O’Hanlon R et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail, 2007 Feb, 13(1): 50-5.
17. McCullough PA et al. Galectin-3: A Novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med, 2011, 12(4): 200-210.
18. Calvier L et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Atheroscler Thromb Vasc Biol, 2013, 33(1): 67–75
19. Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, Badings E, Lipsic E, van Wijngaarden J et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol, 2013, 102(2): 103–110.
20. De Boer RA, Lok DJA, Jaarsma T, van der Meer P, Voors AA, Hillege HL et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med., 2011, 43(1): 60–68.
21. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol, 2008, 172: 288-298.
Review
For citations:
Gyamdzhyan KA, Kukes VG, Maksimov ML. CLINICAL VALUE OF DETERMINING GALECTIN-3 IN PATIENTS WITH CHRONIC HEART FAILURE. Meditsinskiy sovet = Medical Council. 2017;(7):63-68. (In Russ.) https://doi.org/10.21518/2079-701X-2017-7-63-68
Views:
1190
Email this article 